Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...

A post-earnings rally in Hims & Hers Health Inc. has turned co-founder and Chief Executive Officer Andrew Dudum into a weight-loss billionaire.

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

Hims & Hers Health, Inc. (HIMS) could be a solid addition to your portfolio given a notable revision in the company's ...

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Hims & Hers reports 111% YoY sales growth & 70%+ gross margin. Discover their growth potential, risks, & why it's a Buy ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

Hims & Hers ( HIMS 19.03%) stock soared 18.2% in trading on Tuesday after the company reported first-quarter revenue growth ...

Novo Nordisk says it's now cutting its annual outlook - seeing sales growth, at constant exchange rates, between 13% and 21%, vs. its previous forecast of 16% to 24%, and operating profit growth ...